All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

ABBVAbbVie
1Calm
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Running, no new patientsPhase 266 patientsMain results: Dec 2030
AZNAstraZeneca
0Calm
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Running, no new patientsPhase 1/294 patientsMain results: Dec 13, 2027
NVSNovartis Pharmaceuticals
5Calm
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
Running, no new patientsPhase 31,000 patientsMain results: Jul 21, 2026
AZNAstraZeneca
0Calm
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
Running, no new patientsPhase 272 patientsMain results: Nov 4, 2024
NVSNovartis Pharmaceuticals
5Calm
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Running, no new patientsPhase 1/2164 patientsMain results: May 25, 2027
GILDKite, A Gilead Company
1Calm
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
FinishedPhase 295 patientsMain results: Jun 17, 2025
AZNAstraZeneca
0Calm
A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
Running, no new patientsPhase 237 patientsMain results: Mar 13, 2028
REGNRegeneron Pharmaceuticals
5Calm
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Signing up patientsPhase 1/2220 patientsMain results: Aug 20, 2028
NVSNovartis Pharmaceuticals
5Calm
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
Running, no new patientsPhase 31,007 patientsMain results: Jul 22, 2026
AZNAstraZeneca
0Calm
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Running, no new patientsPhase 3895 patientsMain results: Jul 30, 2021
AZNAstraZeneca
0Calm
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Running, no new patientsPhase 3893 patientsMain results: Nov 1, 2027
INCYIncyte Corporation
0Calm
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
FinishedPhase 1/261 patientsMain results: Aug 25, 2025
INCYIncyte Corporation
0Calm
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Running, no new patientsPhase 210 patientsMain results: Sep 30, 2027
AZNAstraZeneca
0Calm
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Running, no new patientsPhase 3293 patientsMain results: Oct 31, 2026
LLYLoxo Oncology, Inc.
0Calm
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Signing up patientsPhase 3737 patientsMain results: Oct 2027
KYNBKyntra Bio
0Calm
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Signing up patientsPhase 275 patientsMain results: Mar 31, 2028
SNYSanofi
0Calm
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Running, no new patientsPhase 32,500 patientsMain results: Apr 30, 2029
PBYIPuma Biotechnology, Inc.
0Calm
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Signing up patientsPhase 2120 patientsMain results: Oct 30, 2027
BMYBristol-Myers Squibb
10Calm
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Signing up patientsPhase 1/21,109 patientsMain results: Aug 31, 2031
RNACCartesian Therapeutics
2Calm
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
Running, no new patientsPhase 230 patientsMain results: Jan 5, 2026
AZNAstraZeneca
0Calm
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Signing up patientsPhase 3750 patientsMain results: Jan 11, 2029
ABBVAbbVie
1Calm
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Signing up patientsPhase 2100 patientsMain results: Dec 2030
MRKMerck Sharp & Dohme LLC
5Calm
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Running, no new patientsPhase 2329 patientsMain results: Aug 12, 2025
CLRBCellectar Biosciences, Inc.
0Calm
Evaluation of Iopofosine I 131 vs. R-CD in WM Patients
Not started yetPhase 3219 patientsMain results: Jan 2032
BMYMirati Therapeutics Inc.
10Calm
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Running, no new patientsPhase 2200 patientsMain results: Oct 30, 2026